Speaker 1: Dan Rujescu, Germany

In contrast to the traditional viewpoint of psychopathology, which compulsivity [a repetitive ritualistic behavior which persists albeit its inappropriateness to the given situation and often result in undesirable consequences] and impulsivity [which encompasses actions that are insufficiently conceived, prematurely expressed, excessively risky or inappropriate to the situation, and that often lead to undesirable outcomes] were positioned at opposite ends of a behavioral characteristics, recent neuroimaging studies raise the possibility of compulsivity and impulsivity being orthogonal factors that each contribute in varying degrees to various psychiatric conditions, including obsessive-compulsive disorder (OCD). In this presentation, I firstly will discuss two differential facets of compulsivityimpulsivity using the clinical (compulsion sub-score of Y-BOCS) and neurocognitive (stop signal task) measures and examined their neural underpinning as reflected in the small-world network of structural (DTI) and resting state functional connectivity network in OCD subjects. Later on, this presentation will also discuss the relationship between OCD and substancerelated and addictive disorders (as defined in the DSM-5) from the spectrum-wise perspective of compulsivity and impulsivity, also using the frame of structural and functional connectome, to widen our understanding for clinical and neurocognitive dimensions of compulsivity-impulsivity phenomena. Speaker 4: Jon Grant, USA Title: Treatment of Compulsive and Impulsive Disorders Abstract Impulsivity and compulsivity have been considered opposite poles of a continuous spectrum, but their relationship appears to be more complex. Disorders characterized by impulsivity often have features of compulsivity and vice versa. The overlaps of the constructs of compulsivity and impulsivity, as well as their differences, suggest different pharmacological targets may be warranted. This presentation will discuss novel pharmacological interventions for compulsive and impulsive behaviors. Many of the pharmacological options that reduce impulsive or compulsive behaviors in certain disorders may be useful for these cognitive domains seen in other disorders. For the purposes of this talk, I will focus on several classes of pharmacological agents and discuss to what extent they may be effective in reducing impulsivity and compulsivity. Of course, there are multiple forms of impulsivity and compulsivity, and different forms of each can co-occur within the same person. In some cases, there are data regarding which type of impulsivity or compulsivity the pharmacological agent is targeting. In those cases, this talk will discuss the subtype in more detail. Additionally, the presentation will discuss the implications of basic neuroscience for developing novel neuropsychopharmacological interventions, and the relevant clinical evidence-base.Impulsivity and compulsivity have been considered opposite poles of a continuous spectrum, but their relationship appears to be more complex. Disorders characterized by impulsivity often have features of compulsivity and vice versa. The overlaps of the constructs of compulsivity and impulsivity, as well as their differences, suggest different pharmacological targets may be warranted. This presentation will discuss novel pharmacological interventions for compulsive and impulsive behaviors. Many of the pharmacological options that reduce impulsive or compulsive behaviors in certain disorders may be useful for these cognitive domains seen in other disorders. For the purposes of this talk, I will focus on several classes of pharmacological agents and discuss to what extent they may be effective in reducing impulsivity and compulsivity. Of course, there are multiple forms of impulsivity and compulsivity, and different forms of each can co-occur within the same person. In some cases, there are data regarding which type of impulsivity or compulsivity the pharmacological agent is targeting. In those cases, this talk will discuss the subtype in more detail. Additionally, the presentation will discuss the implications of basic neuroscience for developing novel neuropsychopharmacological interventions, and the relevant clinical evidence-base.